Inactive Instrument

Highlights Presbia PLC Nasdaq

Equities

Presbia plc Reports Earnings Results for the Full Year Ended December 31, 2018	19-04-12	CI
Presbia PLC Provides Update on U.S. Staged Pivotal Clinical Trial	16-12-22	CI
Presbia Seeks Acqusitions	16-12-05	CI
Presbia PLC Completes 6-Month Post-Operative Visits	16-05-31	CI
Presbia PLC Seeks Acquisition	16-04-15	CI
Presbia Announces First Patients in Presbia Microlens Fda Study Complete 12-Month Postoperative Visits	16-03-01	CI
Presbia Introduces Time-Saving Disposable Microlens Inserter	15-10-05	CI
Presbia PLC to Complete Second Stage Enrollment in the FDA Pivotal Study of Presbia Flexivue Microlens	15-09-03	CI
Presbia Surpasses Treatment of 300 Subjects as Part of the US FDA Pivotal Study Enrollment	15-08-10	CI
Presbia PLC Reaches the Halfway Mark in Second Stage Enrollment in the US FDA Pivotal Study	15-07-09	CI
Presbia PLC Receives Approval from FDA to Commence Second Stage Enrollment in the Pivotal Trial of the Presbia Flexivue Microlens	15-02-09	CI
Presbia PLC has completed an IPO in the amount of $41.67 million.	15-01-28	CI
Presbia PLC has filed an IPO in the amount of $90.00 million.	14-03-20	CI

No results for this search